MarkPhilipBreazzanoMDFACS

Ophthalmology • Rochester, NY

Retinal Disease

Associate Professor and Vitreoretinal Fellowship Director, Flaum Eye Institute/University of Rochester Medical Center

Join to view full profile

Dr. Breazzano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Breazzano's full profile

Already have an account?

Office
210 Crittenden Blvd
Rochester, NY 14642

Clinical Expertise

Diabetic retinopathy, Macular surgery, Retinal disease, Macular degeneration, Retinal detachment, Vitrectomy, Vitreous hemorrhage, Retina surgery, Central retinal vein occlusion, Macular pucker, Retinal degeneration, Vitreoretinal disease, Proliferative vitreoretinopathy, Branch retinal vein occlusion

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Surgical Retina and Vitreous, 2018 - 2020
Vanderbilt University Medical CenterResidency, Ophthalmology, 2015 - 2018
Yale-New Haven Medical CenterInternship, Transitional Year, 2014 - 2015
SUNY Upstate Medical UniversityClass of 2014

Certifications & Licensure

NY State Medical License 2018 - 2027
MD State Medical License 2020 - 2022
American Board of Ophthalmology Ophthalmology

Clinical Trials

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) Start of enrollment: 2021 Mar 12
Recruiting
Phase 3
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment Start of enrollment: 2023 Apr 04
Completed
Phase 2
Fenofibrate for Prevention of DR Worsening Start of enrollment: 2021 Mar 05
Recruiting
Phase 3
Evaluation of Tonabersat for DME Start of enrollment: 2023 May 02
Recruiting
Phase 2
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM Start of enrollment: 2022 Feb 22
Recruiting
Not Applicable
Nesvategrast (OTT166) in Diabetic Retinopathy (DR) Start of enrollment: 2022 Jul 29
Completed
Phase 2
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Start of enrollment: 2023 Mar 06
Recruiting
Phase 2
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) Start of enrollment: 2019 Jan 08
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Start of enrollment: 2018 Sep 05
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) Start of enrollment: 2019 Feb 19
Completed
Phase 3
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema Start of enrollment: 2020 Aug 05
Completed
Phase 3
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) Start of enrollment: 2020 Aug 25
Recruiting
Phase 2
A Study of NGM621 in Participants With Geographic Atrophy Start of enrollment: 2020 Jul 22
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Start of enrollment: 2021 Mar 02
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Start of enrollment: 2021 Mar 02
Completed
Phase 3
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) Start of enrollment: 2019 Jun 03
Terminated
Phase 2
A Study Assessing Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) Start of enrollment: 2021 Dec 14
Recruiting
Phase 4
FIGHT-RP 1 Extension Study Start of enrollment: 2019 Jun 24
Active, not recruiting
Phase 1
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration Start of enrollment: 2021 Apr 19
Active, not recruiting
Phase 3
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) Start of enrollment: 2020 Nov 20
Recruiting
Phase 2
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Diabetic Macular Edema Start of enrollment: 2021 Oct 19
Active, not recruiting
Phase 2, Phase 3
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema Start of enrollment: 2020 Jul 31
Completed
Phase 2
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Start of enrollment: 2022 Sep 26
Active, not recruiting
Phase 3
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) Start of enrollment: 2022 Jul 28
Active, not recruiting
Phase 2
Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration Start of enrollment: 2020 Oct 28
Recruiting
Phase 1
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Start of enrollment: 2023 Jun 12
Recruiting
Phase 1, Phase 2
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema Start of enrollment: 2024 Jan 09
Recruiting
Phase 2
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration Start of enrollment: 2024 Jan 31
Recruiting
Phase 2
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products Start of enrollment: 2022 Nov 21
Recruiting
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) Start of enrollment: 2024 Jan 24
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

32 citations
Frequency of Urgent or Emergent Vitreoretinal Surgical Procedures in the United States During the COVID-19 Pandemic.
Mark P. Breazzano, Archana A Nair, J. Fernando Arevalo, Mark R. Barakat, Audina M. Berrocal
JAMA Ophthalmology. 2021-04-01
17 citations
Central serous chorioretinopathy: An evidence-based treatment guideline.
Helena M A Feenstra, Elon H C van Dijk, Chui Ming Gemmy Cheung, Kyoko Ohno-Matsui, Timothy Y Y Lai
Progress in Retinal and Eye Research. 2024-07-01
12 citations
Prospective analysis of pediatric ocular chemical burns: laundry detergent pods
Mark P. Breazzano, H. Russell Day, Sarah Tanaka, Uyen Tran
Journal of AAPOS. 2018-10-17

Journal Articles

CLEARED (Chemicals and Litmus Testing with Effective Alkaline Range for Eye Damage): A Prospective, Interventional Study
Uyen Tran, Mark P Breazzano, Sarah Tanaka, Academic emergency medicine